14 Jun Drug Discovery News: A cell therapy to heal a broken heart
Researchers harvest stem cells from patients who have recently had a heart attack and use them to trigger regeneration of their cardiac muscle.
Press clips
13 Jun Drug Development & Delivery: CellProthera Announces Positive Phase 1/2b Data for ProtheraCytes Cell Therapy in Acute Myocardial Infarction
CellProthera recently announced positive results from a Phase 1/2b study of its lead ProtheraCytes in patients following a severe heart attack, positioning the stem cell therapy as a promising option to repair and regenerate heart tissue. The data was presented today by Faiez Zannad, MD, PhD, Chairman of the study’s steering committee and emeritus professor of therapeutics at the Université of Lorraine.
16 Apr DDW: 2024 predictions: Experts weigh in on stem cells
DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on the future of stem cells in drug discovery.
16 Apr EUROPEAN PHARMACEUTICAL MANUFACTURER: Optimising TIME-TO-MARKET for innovative cell therapy
Didier HAGUENAUER - CMO - CELLPROTHERA
29 Feb PHARMIWEB: CellProthera collaborates with Japanese stem cell experts…
CellProthera collaborates with Japanese stem cell experts at Shonan-Kamakura General Hospital (SKGH) on clinical manufacturing for upcoming autologous stem cell trials in ischemic diseases
10 Nov LE FIGARO | DOSSIER SANTE – Stem cells : a promise that is becoming a reality
A 20 year old promise slowly becoming a reality
04 Oct University Hospitals Birmingham Connected: Heart patient given new lease of life
Kim Smith, a 66-year-old heart attack patient, experienced a life-changing breaktrough after receiving stem cell therapy at Queen Elizabeth Hospital Birmingham (QEHB)
26 Sep PHARMIWEB: CellProthera completes enrollment in Phase I/IIB trial for post-myocardial infarction cell therapy
Final patient receives ProtheraCytes(R) cell therapy to regenerate damaged heart tissue following severe heart attack. Study remains on track for final readout in H1 2024
31 Jul DDW – Turning science into business: Can regenerative medicine treat heart attacks?
DDW’s Reece Armstrong speaks to Hendrik Streefkerk, Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases.
30 Jun MED-TECH INNOVATION | NEWS: Trans-endocardial delivery: The importance of the right solution
Peter Altman, CEO of BioCardia, and Matthieu de Kalbermatten, CEO of CellProthera, comment on trans-endocardial intramyocardial delivery systems for biotherapeutics to treat heart failure, ischemia, and infarction, and the importance of the right delivery solution.